Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement - Wikidata - wikimedia - TriplyDB

Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement

Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement

http://www.wikidata.org/entity/Q36062295

about

Pharmacogenetics-based warfarin dosing in children Warfarin pharmacogenetics: does more accurate dosing benefit patients?Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis Warfarin Pharmacogenetics: New Life for an Old Drug The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.Pharmacogenetics of warfarin: challenges and opportunities.Characterizing variability in warfarin dose requirements in children using modelling and simulation.Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children Revisiting Warfarin Dosing Using Machine Learning Techniques.Effects of VKORC1 Genetic Polymorphisms on Warfarin Maintenance Dose Requirement in a Chinese Han Population.Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models.Warfarin pharmacogenomics in children.Pharmacogenetics in clinical pediatrics: challenges and strategies.Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients.Pharmacogenetic Markers of Drug Efficacy and Toxicity.Genetic and clinical determinants influencing warfarin dosing in children with heart disease.VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.Dosage individualization of warfarin using artificial neural networks.The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.

P2860

Q27008320-3582AC2F-3A26-47BD-B0FD-8062D6964E15 Q27027304-48DBA893-05BD-4CC6-925D-2F57178B556E Q28071448-290895E0-DE2D-4DA8-92D9-0BB7C4FA628D Q28276605-85728970-DF2C-45FF-B8B9-75027633A5B3 Q28468726-F62AE4FE-6505-45CD-9A30-B5C4C83D30BB Q33707218-A354EF17-B81E-4225-8287-FC245205C16D Q33819050-B5A108E5-5CDF-48F3-9B6F-F8333DD2C86C Q34209582-E96E2B29-9B43-46BE-B54C-5C7A5E560AA2 Q34402967-100BA27E-567D-4A76-97A2-FCFEE4E74752 Q35608926-7E271EEE-AE08-4E0F-BC2E-D9AF9DE0E5DD Q35753465-BB0EE867-7ECC-472D-BA06-ABD8A05C62F1 Q36314728-878BF975-753A-4CF3-AE5E-31DDAEEFFB7F Q36836979-0F9E4458-E503-4B30-9F33-2FF51EB063A8 Q37115651-E4AC7FDC-4C74-4401-899F-CB3C935AD430 Q37205695-5DCAAD8E-CC9B-4557-BDB8-431AAF10E207 Q37400384-FB1C926A-BFE5-4C7E-BD01-3F8D4B1D2DBD Q38078754-0849F54C-AA8F-4FCE-8FD6-7F072C9A888D Q38116770-9996D033-1D12-4AF2-AEFF-CB88D1957842 Q38419534-65660518-6CA9-4926-B9A6-675F2121A2F8 Q39513879-4101BF47-9241-47AB-9DCD-70E86141B42D Q42707118-5F9C9EDF-B836-4264-A76E-F6CE94FC67D0 Q44367614-260752CE-BD69-462B-9B2E-6E815B1F8710 Q47570862-AA00FDA0-3943-4A87-B074-4E7A58360A7D Q47778292-9582C9EA-A9CF-4074-81F3-348B114D3667 Q51107902-0257F956-8853-4DA2-8151-288B7F015A15 Q53695415-C3BD90B8-3B9F-4504-A270-394D668A9CC8

P2860

Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement

http://www.wikidata.org/entity/Q36062295

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Vitamin K antagonists in child ...... the warfarin dose requirement

@ast

Vitamin K antagonists in child ...... the warfarin dose requirement

@en

type

label

Vitamin K antagonists in child ...... the warfarin dose requirement

@ast

Vitamin K antagonists in child ...... the warfarin dose requirement

@en

prefLabel

Vitamin K antagonists in child ...... the warfarin dose requirement

@ast

Vitamin K antagonists in child ...... the warfarin dose requirement

@en

P1433

Q36062295-6B333E11-FA30-4557-9EB6-BB74F05F8140

P1476

Q36062295-7F77F117-0406-46B3-8602-94B3AD3D11A2

P2093

Q36062295-00B1307C-89C7-4F82-950E-114B5EECB665

Q36062295-31B1F50E-07CF-4725-8C57-D5AFED0481F3

Q36062295-32EE48EE-D173-44F5-A76D-1977DBE2DAC6

Q36062295-3B18A11E-ADC7-46D7-A233-226A74DF5115

Q36062295-4A7886D4-5733-40F5-BF3B-9F3F87D07982

Q36062295-58005586-E08D-4CD7-A396-47582CF9C615

Q36062295-5C2A424A-2B3D-46CD-8E10-5EDC8407AA24

Q36062295-7ECE2311-AD5B-4E2B-A7B3-73E8FF26C297

Q36062295-BDEF6C74-2C81-4179-9754-F382E7A90FEC

Q36062295-FDAEAB23-8B6B-46C3-B158-CCE93B4D576B

P2860

Q36062295-043C9257-6352-45B9-8746-F6452617A82B

Q36062295-11A23A28-1483-4175-AD77-F2A946EC02D8

Q36062295-15689374-DB86-412D-B861-8A9393DCF6F8

Q36062295-183E6FA4-654B-455B-AE0F-38B7B72FA373

Q36062295-2C3BE945-CC6C-430C-8137-6F51D2048B78

Q36062295-3A5B970B-36FC-4997-BA19-ABBF8ACCB36D

Q36062295-40EFE290-FDBA-4DBA-BDFB-BFA413B68302

Q36062295-464552EE-8ED7-4DF5-A5AA-B6A3F74C2985

Q36062295-4E670318-C18B-4F60-B2E8-ED3E47E089AE

Q36062295-50EF3FE2-FB52-461A-AFFC-A2B9DD1A48F2

P304

Q36062295-537717BE-7FA3-4C0A-BA64-99C76FF6BCFB

P31

Q36062295-6D172F38-4FFF-40E9-8015-024A5ADA8C6D

P356

Q36062295-C8DB98F7-E719-4BD7-B136-87F7CB37DA4A

P407

Q36062295-2EE987C4-6296-48A0-8A35-407EBA1794FA

P433

Q36062295-F05F8239-5BEF-4E87-84C5-FCC453C6E2F5

P478

Q36062295-D4D797C9-386C-4A4B-AF7A-1BDA972DCDC5

P577

Q36062295-D5E339F1-6054-486B-B920-CF1EA6AE7F58

P5875

Q36062295-1B557DCE-0B0F-475F-A69B-2E5BBF7752B4

P698

Q36062295-78D8B9D8-3C0A-426F-A1CD-DE616B82CA98

P921

Q36062295-7f8115ad-6fa6-4224-8dec-8973bd7303b5

P932

Q36062295-A9ACBD14-6ECE-4A44-97AA-EE1F892671D6

P356

BLOOD-2011-07-365502

P1433

P1476

Vitamin K antagonists in child ...... the warfarin dose requirement

@en

P2093

Caroline Elie

http://www.w3.org/2001/XMLSchema#string

Caroline Moreau

http://www.w3.org/2001/XMLSchema#string

Damien Bonnet

http://www.w3.org/2001/XMLSchema#string

Dominique Lasne

http://www.w3.org/2001/XMLSchema#string

Fanny Bajolle

http://www.w3.org/2001/XMLSchema#string

Jean-Louis Golmard

http://www.w3.org/2001/XMLSchema#string

Marie-Anne Loriot

http://www.w3.org/2001/XMLSchema#string

Philippe Beaune

http://www.w3.org/2001/XMLSchema#string

Radhia Cheurfi

http://www.w3.org/2001/XMLSchema#string

Virginie Siguret

http://www.w3.org/2001/XMLSchema#string

P2860

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

Estimation of the warfarin dose with clinical and pharmacogenetic data.

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

The vitamin K cycle.

CYP4F2 genetic variant alters required warfarin dose

Genetic determinants of response to warfarin during initial anticoagulation

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans

The largest prospective warfarin-treated cohort supports genetic forecasting

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy

P304

861-867

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-07-365502

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51843361

http://www.w3.org/2001/XMLSchema#string

P698

22130800

http://www.w3.org/2001/XMLSchema#string

P921

P932

3384479

http://www.w3.org/2001/XMLSchema#string